Cargando…
Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis
Background: Liver fibrosis is a common outcome of the pathological progression of chronic liver disease; however, no specific and effective therapeutic agent has been approved for its treatment. We investigated the effects of Kuhuang on liver fibrosis and the underlying mechanisms of action. Materia...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792617/ https://www.ncbi.nlm.nih.gov/pubmed/36582518 http://dx.doi.org/10.3389/fphar.2022.1080226 |
_version_ | 1784859675807711232 |
---|---|
author | Shen, Bo Zhou, Cui Gu, Tianyi Shen, Zhenyang Guo, Yuecheng Dai, Weiming Liu, Yang Zhang, Jie Lu, Lungen Dong, Hui |
author_facet | Shen, Bo Zhou, Cui Gu, Tianyi Shen, Zhenyang Guo, Yuecheng Dai, Weiming Liu, Yang Zhang, Jie Lu, Lungen Dong, Hui |
author_sort | Shen, Bo |
collection | PubMed |
description | Background: Liver fibrosis is a common outcome of the pathological progression of chronic liver disease; however, no specific and effective therapeutic agent has been approved for its treatment. We investigated the effects of Kuhuang on liver fibrosis and the underlying mechanisms of action. Materials and methods: To induce hepatic fibrosis, either 3,5-diethoxycarbonyl-1,4-dihydro-collidine (DDC) diet was administered, or bile duct ligation (BDL) surgery was performed on C57BL/6 mice. Kuhuang was orally administered to mice for 7 days before and after bile duct ligation or 4 weeks with a DDC diet. Hematoxylin and eosin, Sirius red staining, and immunohistochemical analyses were performed to evaluate hepatic pathology. Hepatic interferon-β (IFN-β) levels were measured using an enzyme-linked immunosorbent assay. RNA sequencing was performed to examine the gene expression profiles of liver tissues. The mRNA expression of inflammatory, profibrotic, and bile acid (BA)-related genes was further validated by qRT-PCR. A targeted metabolomics assay revealed the alteration of the hepatic bile acid (BA) composition. The composition of the gut microbiota was determined via 16S rRNA sequencing. Results: Treatment with Kuhuang attenuated liver fibrosis and reduced the inflammatory response in bile duct ligation and DDC mouse models. In addition, the hepatic IFN signaling pathway was activated following Kuhuang treatment. Kuhuang treatment also significantly decreased hepatic levels of both primary and secondary BAs. In addition, Kuhuang treatment altered gut microbiota composition, with an increased abundance of interferon-inducing Akkermansia and decreased abundance of bile salt hydrolase-producing Lactobacillus, Clostridium, and Bifidobacterium. Furthermore, the abundance of Akkermansia was positively correlated with the hepatic mRNA expression levels of Ifna4, Ifnb, and Isg15, whereas that of Lactobacillus, Clostridium ( - ) sensu ( - ) stricto ( - ) 1, and Bifidobacterium was positively correlated with levels of bile acid synthesis-related genes. Conclusion: Our results suggest that Kuhuang plays a protective role during the progression of liver fibrosis, potentially by altering the composition of the gut microbiota, which consequently activates interferon signaling and inhibits bile acid synthesis in the liver. |
format | Online Article Text |
id | pubmed-9792617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97926172022-12-28 Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis Shen, Bo Zhou, Cui Gu, Tianyi Shen, Zhenyang Guo, Yuecheng Dai, Weiming Liu, Yang Zhang, Jie Lu, Lungen Dong, Hui Front Pharmacol Pharmacology Background: Liver fibrosis is a common outcome of the pathological progression of chronic liver disease; however, no specific and effective therapeutic agent has been approved for its treatment. We investigated the effects of Kuhuang on liver fibrosis and the underlying mechanisms of action. Materials and methods: To induce hepatic fibrosis, either 3,5-diethoxycarbonyl-1,4-dihydro-collidine (DDC) diet was administered, or bile duct ligation (BDL) surgery was performed on C57BL/6 mice. Kuhuang was orally administered to mice for 7 days before and after bile duct ligation or 4 weeks with a DDC diet. Hematoxylin and eosin, Sirius red staining, and immunohistochemical analyses were performed to evaluate hepatic pathology. Hepatic interferon-β (IFN-β) levels were measured using an enzyme-linked immunosorbent assay. RNA sequencing was performed to examine the gene expression profiles of liver tissues. The mRNA expression of inflammatory, profibrotic, and bile acid (BA)-related genes was further validated by qRT-PCR. A targeted metabolomics assay revealed the alteration of the hepatic bile acid (BA) composition. The composition of the gut microbiota was determined via 16S rRNA sequencing. Results: Treatment with Kuhuang attenuated liver fibrosis and reduced the inflammatory response in bile duct ligation and DDC mouse models. In addition, the hepatic IFN signaling pathway was activated following Kuhuang treatment. Kuhuang treatment also significantly decreased hepatic levels of both primary and secondary BAs. In addition, Kuhuang treatment altered gut microbiota composition, with an increased abundance of interferon-inducing Akkermansia and decreased abundance of bile salt hydrolase-producing Lactobacillus, Clostridium, and Bifidobacterium. Furthermore, the abundance of Akkermansia was positively correlated with the hepatic mRNA expression levels of Ifna4, Ifnb, and Isg15, whereas that of Lactobacillus, Clostridium ( - ) sensu ( - ) stricto ( - ) 1, and Bifidobacterium was positively correlated with levels of bile acid synthesis-related genes. Conclusion: Our results suggest that Kuhuang plays a protective role during the progression of liver fibrosis, potentially by altering the composition of the gut microbiota, which consequently activates interferon signaling and inhibits bile acid synthesis in the liver. Frontiers Media S.A. 2022-12-13 /pmc/articles/PMC9792617/ /pubmed/36582518 http://dx.doi.org/10.3389/fphar.2022.1080226 Text en Copyright © 2022 Shen, Zhou, Gu, Shen, Guo, Dai, Liu, Zhang, Lu and Dong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Shen, Bo Zhou, Cui Gu, Tianyi Shen, Zhenyang Guo, Yuecheng Dai, Weiming Liu, Yang Zhang, Jie Lu, Lungen Dong, Hui Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis |
title | Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis |
title_full | Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis |
title_fullStr | Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis |
title_full_unstemmed | Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis |
title_short | Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis |
title_sort | kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic ifn signaling and bile acid synthesis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792617/ https://www.ncbi.nlm.nih.gov/pubmed/36582518 http://dx.doi.org/10.3389/fphar.2022.1080226 |
work_keys_str_mv | AT shenbo kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis AT zhoucui kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis AT gutianyi kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis AT shenzhenyang kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis AT guoyuecheng kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis AT daiweiming kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis AT liuyang kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis AT zhangjie kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis AT lulungen kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis AT donghui kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis |